#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Atypical haemolytic uraemic syndrome Propionic acidaemia Pyoderma gangrenosum Myxoid liposarcoma Lip and/or oral cavity cancer Extranodal marginal zone B-cell lymphoma (MALT type) Carcinoid tumour Univentricular heart Macular telangiectasia Vulval cancer recurrent Krabbe's disease Ewing's sarcoma recurrent Vitamin B12 deficiency Heavy menstrual bleeding Astrocytoma More trials…

    Learn about Rare Diseases

    Uterine leiomyosarcoma – Diagnostics Chondrosarcoma – Life with Disease Loeys-Dietz syndrome Advanced systemic mastocytosis – Diagnostics Leiomyosarcoma recurrent – Trials in Disease Skin angiosarcoma – Basic Information Leukoencephalopathy Osteosarcoma metastatic – Basic Information Cerebral arteriovenous malformation haemorrhagic – Trials in Disease Optic glioma – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Guselkumab Abc-35B-116 AZD0022 Dexamethasone Acetate Ph. Eur. Phenylephrine Iti-1284 Promethazine Hydrochloride Micronised Spironolactone Baxdrostat Urea Sodium Thiosulfate Durvalumab Binimetinib Tumor Necrosis Factor-Alpha Nitrofurantoin DIMENHYDRINATE NVG-2089 Interferon Alfa [14C]ZIPALERTINIB Doxecitine More therapies…

    Learn about Your Condition

    Fracture infection Venous thrombosis Patent ductus arteriosus Apheresis Biopsy heart Systemic lupus erythematosus Partial seizures Rhabdomyosarcoma recurrent Infective uveitis Chondropathy Chondrocalcinosis Periarthritis Splenic marginal zone lymphoma Oral lichen planus Mucopolysaccharidosis III More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Nervous System Diseases

  • Study on the Effectiveness of Autologous Stem Cell Transplantation with Cytarabine in Patients with Aggressive Multiple Sclerosis

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Alemtuzumab
    • Anti-Human T-Lymphocyte Immunoglobulin From Rabbits
    • Melphalan Flufenamide
    Italy

  • Study on the Effects of TTI-0102 for Patients with MELAS Syndrome

    Not recruiting

    2 1
    Investigated Drugs:
    • Mercaptamine-Pantetheine Disulfide Acetate
    France The Netherlands

  • Study on the Safety and Effects of BIIB122 for Patients with LRRK2-Associated Parkinson’s Disease

    Not recruiting

    2 1
    Investigated Diseases:
    • Parkinson’s disease
    Investigated Drugs:
    • N2-(3-(2-(2H-1,2,3-Triazol-2-Yl)Propan-2-Yl)-1-Cyclopropyl-1H-Pyrazol-5-Yl)-N4-Ethyl-5-(Trifluoromethyl)Pyrimidine-2,4-Diamine
    Germany Spain

  • Study on Frexalimab for Adults with Nonrelapsing Secondary Progressive Multiple Sclerosis

    Not recruiting

    3 1
    Investigated Drugs:
    • Frexalimab
    Belgium Bulgaria Czechia France Germany Greece +7

  • Study on the Safety and Effects of LY3372689 in Patients with Early Alzheimer’s Disease

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Dementia Alzheimer’s type
    Investigated Drugs:
    • Flortaucipir (18F)
    • N-[4-Fluoro-5-[[2S,4S)-2-Methyl-4-[(5-Methyl-1,2,4-Oxadiazol-3-Yl)Methoxy]-1-Piperidinyl]Methyl]-2-Thiazolyl-Acetamide
    Poland

  • Study on Tolebrutinib for Patients with Primary Progressive Multiple Sclerosis

    Not recruiting

    3 1
    Investigated Diseases:
    • Primary progressive multiple sclerosis
    Investigated Drugs:
    • Tolebrutinib
    Austria Belgium Bulgaria Croatia Czechia Denmark +13
Previous Page
1 … 94 95 96 97 98 … 142
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!